160 related articles for article (PubMed ID: 34237407)
1. PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.
Jin P; Li J; Meng Y; Wu L; Bai M; Yu J; Meng X
Cancer Lett; 2021 Nov; 520():91-99. PubMed ID: 34237407
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
3. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
[TBL] [Abstract][Full Text] [Related]
4. Immune PET Imaging.
Iyalomhe O; Farwell MD
Radiol Clin North Am; 2021 Sep; 59(5):875-886. PubMed ID: 34392924
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Cho SY; Huff DT; Jeraj R; Albertini MR
Semin Nucl Med; 2020 Nov; 50(6):518-531. PubMed ID: 33059821
[TBL] [Abstract][Full Text] [Related]
6. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of
Iravani A; Hicks RJ
J Nucl Med; 2020 Jul; 61(7):943-950. PubMed ID: 32444375
[TBL] [Abstract][Full Text] [Related]
7. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
8. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
Iravani A; Hicks RJ
J Nucl Med; 2020 Nov; 61(11):1553-1559. PubMed ID: 32887755
[TBL] [Abstract][Full Text] [Related]
9.
Prigent K; Aide N
PET Clin; 2020 Jan; 15(1):1-10. PubMed ID: 31735296
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy-related adverse effects on
Gandy N; Arshad MA; Wallitt KL; Dubash S; Khan S; Barwick TD
Br J Radiol; 2020 Jul; 93(1111):20190832. PubMed ID: 32105505
[No Abstract] [Full Text] [Related]
11. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
Aide N; Hicks RJ; Le Tourneau C; Lheureux S; Fanti S; Lopci E
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):238-250. PubMed ID: 30291373
[TBL] [Abstract][Full Text] [Related]
12. PET/CT and the Response to Immunotherapy in Lung Cancer.
Evangelista L; Sepulcri M; Pasello G
Curr Radiopharm; 2020; 13(3):177-184. PubMed ID: 31858908
[TBL] [Abstract][Full Text] [Related]
13. Update on tumor metabolism and patterns of response to immunotherapy.
Castello A; Lopci E
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):175-185. PubMed ID: 32107904
[TBL] [Abstract][Full Text] [Related]
14. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
15. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.
Unterrainer M; Ruzicka M; Fabritius MP; Mittlmeier LM; Winkelmann M; Rübenthaler J; Brendel M; Subklewe M; von Bergwelt-Baildon M; Ricke J; Kunz WG; Cyran CC
Eur Radiol Exp; 2020 Nov; 4(1):63. PubMed ID: 33200246
[TBL] [Abstract][Full Text] [Related]
16. The value of
Ayati N; Sadeghi R; Kiamanesh Z; Lee ST; Zakavi SR; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):428-448. PubMed ID: 32728798
[TBL] [Abstract][Full Text] [Related]
17. Is
Karlsen W; Akily L; Mierzejewska M; Teodorczyk J; Bandura A; Zaucha R; Cytawa W
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893111
[TBL] [Abstract][Full Text] [Related]
18. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
19. Is there a link between very early changes of primary and secondary lymphoid organs in
Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]